Resveratrol in management of bone and spinal cancers

References

• Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM. 2006. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol. 19:1512–1518.
   PubMed Web of Science ®Google Scholar
• Alkhalaf M, Jaffal S. 2006. Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic Biol Med. 41:318–325.10.1016/j.freeradbiomed.2006.04.019
   PubMed Web of Science ®Google Scholar
• Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, et al. 2011. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 224:334–343.10.1002/path.v224.3
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Erlandson RA, Huvos AG. 2000. Primary fibrosarcoma and malignant fibrous histiocytoma of bone–a comparative ultrastructural study: evidence of a spectrum of fibroblastic differentiation. Ultrastruct Pathol. 24:83–91.10.1080/01913120050118558
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5:493–506.10.1038/nrd2060
   PubMed Web of Science ®Google Scholar
• Bielack S, Carrle D. 2009. Casali PG; ESMO guidelines working group. osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20:137–139.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Hecker-Nolting S, Blattmann C, Kager L. 2016. Advances in the management of osteosarcoma. F1000Res. 5:2767.10.12688/f1000research
   PubMedGoogle Scholar
• Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM. 2005. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 65:9943–9952.10.1158/0008-5472.CAN-05-0651
   PubMed Web of Science ®Google Scholar
• Chao SC, Chen YJ, Huang KH, Kuo KL, Yang TH, Huang KY, Wang CC, Tang CH, Yang RS, Liu SH. 2017. Induction of sirtuin-1 signaling by resveratrol induces human chondrosarcoma cell apoptosis and exhibits antitumor activity. Sci Rep. 7:320.10.1038/s41598-017-03635-7
   PubMed Web of Science ®Google Scholar
• Chen BY, Kuo CH, Liu YC, Ye LY, Chen JH, Shieh CJ. 2012. Ultrasonic-assisted extraction of the botanical dietary supplement resveratrol and other constituents of Polygonum cuspidatum. J Nat Prod. 75:1810–1813.10.1021/np300392n
   PubMed Web of Science ®Google Scholar
• Chen B, Yang Y, Chen L, Zhou F, Yang H. 2014. Unilateral lateral mass fixation of cervical spinal low-grade chondrosarcoma with intralesional resection: a case report. Oncol Lett. 7:1515–1518.
   PubMed Web of Science ®Google Scholar
• Chen W, Yeo SC, Elhennawy MG, Xiang X, Lin HS. 2015. Determination of naturally occurring resveratrol analog trans-4,4’-dihydroxystilbene in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Anal Bioanal Chem. 407:5793–5801.10.1007/s00216-015-8762-7
   PubMed Web of Science ®Google Scholar
• Chen W, Yeo SC, Elhennawy MGAA, Lin HS. 2016. Oxyresveratrol: a bioavailable dietary polyphenol. J Funct Foods. 22:122–131.10.1016/j.jff.2016.01.020
   Web of Science ®Google Scholar
• Cheng W, Zhao Y, Liu H, Fan Q, Lu FF, Li J, Yin Q, Yan CD. 2014. Resveratrol attenuates bone cancer pain through the inhibition of spinal glial activation and CX3CR1 upregulation. Fundam Clin Pharmacol. 28:661–670.10.1111/fcp.2014.28.issue-6
   PubMed Web of Science ®Google Scholar
• Cheung MR. 2014. Optimization of predictors of Ewing sarcoma cause-specific survival: a population study. Asian Pac J Cancer Prev. 15:4143–4145.10.7314/APJCP.2014.15.10.4143
   PubMedGoogle Scholar
• Choo QY, Yeo SC, Ho PC, Tanaka Y, Lin HS. 2014. Pterostilbene surpassed resveratrol for anti-inflammatory application: Potency consideration and pharmacokinetics perspective. J Funct Foods. 11:352–362.10.1016/j.jff.2014.10.018
   Web of Science ®Google Scholar
• Dai Z, Lei P, Xie J, Hu Y. 2015. Antitumor effect of resveratrol on chondrosarcoma cells via phosphoinositide 3-kinase/AKT and p38 mitogen-activated protein kinase pathways. Mol Med Rep. 12:3151–3155.10.3892/mmr.2015.3683
   PubMed Web of Science ®Google Scholar
• Darouassi Y, Touati MM, Chihani M, Nadour K, Boussouga M, Ammar H, Bouaity B. 2014. Chondrosarcoma metastasis in the thyroid gland: a case report. J Med Case Rep. 8:426.10.1186/1752-1947-8-157
   PubMedGoogle Scholar
• Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB. 2003. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 102:987–995.10.1182/blood-2002-11-3550
   PubMed Web of Science ®Google Scholar
• Ferry-Dumazet H, Garnier O, Mamani-Matsuda M, Vercauteren J, Belloc F, Billiard C, Dupouy M, Thiolat D, Kolb JP, Marit G, et al. 2002. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis. 23:1327–1333.10.1093/carcin/23.8.1327
   PubMed Web of Science ®Google Scholar
• Frémont L. 2000. Biological effects of resveratrol. Life Sci. 66:663–673.10.1016/S0024-3205(99)00410-5
   PubMed Web of Science ®Google Scholar
• Gao Y, He C, Ran R, Zhang D, Li D, Xiao PG, Altman E. 2015. The resveratrol oligomers, cis- and trans-gnetin H, from Paeonia suffruticosa seeds inhibit the growth of several human cancer cell lines. J Ethnopharmacol. 169:24–33.10.1016/j.jep.2015.03.074
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovee JV. 2008. The clinical approach towards chondrosarcoma. Oncologist. 13:320–329.10.1634/theoncologist.2007-0237
   PubMed Web of Science ®Google Scholar
• Geng S, Zhang J, Zhang LW, Wu Z, Jia G, Xiao X, Hao S. 2014. Diagnosis and microsurgical treatment of chondromas and chondrosarcomas of the cranial base. Oncol Lett. 8:301–304.
   PubMed Web of Science ®Google Scholar
• Gweon EJ, Kim SJ. 2013. Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3 K pathways in HT1080 human fibrosarcoma cells. Oncol Rep. 29:826–834.10.3892/or.2012.2151
   PubMed Web of Science ®Google Scholar
• Gweon EJ, Kim SJ. 2014. Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep. 32:71–78.10.3892/or.2014.3192
   PubMed Web of Science ®Google Scholar
• Harati K, Slodnik P, Chromik AM, Goertz O, Hirsch T, Kapalschinski N, Klein-Hitpass L, Kolbenschlag J, Uhl W, Lehnhardt M, et al. 2015. Resveratrol induces apoptosis and alters gene expression in human fibrosarcoma cells. Anticancer Res. 35:767–774.
   PubMed Web of Science ®Google Scholar
• Hinarejos P, Escuder MC, Monllau JC, Alvarez P, Lloreta J, Ballester J. 2000. Fibrosarcoma at the site of a metallic fixation of the tibia–a case report and literature review. Acta Orthop Scand. 71:329–332.10.1080/000164700317412004
   PubMed Web of Science ®Google Scholar
• Hu K, Dai HB, Qiu ZL. 2016. mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol Rep. 36:1219–1225.10.3892/or.2016.4922
   PubMed Web of Science ®Google Scholar
• Iwamoto Y. 2007. Diagnosis and treatment of Ewing’s sarcoma. Jpn J Clin Oncol. 37:79–89.10.1093/jjco/hyl142
   PubMed Web of Science ®Google Scholar
• Jamil N, Howie S, Salter DM. 2010. Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol. 91:387–393.10.1111/iep.2010.91.issue-5
   PubMed Web of Science ®Google Scholar
• Jin H, Chen H, Yu K, Zhang J, Li B, Cai N, Pan J. 2016. Resveratrol inhibits phosphorylation within the signal transduction and activator of transcription 3 signaling pathway by activating sirtuin 1 in SW1353 chondrosarcoma cells. Mol Med Rep. 14:2685–2690.10.3892/mmr.2016.5554
   PubMed Web of Science ®Google Scholar
• Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, Zhang DZ. 2013. Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Molecules and Cells. 35:219–225.10.1007/s10059-013-2259-z
   PubMed Web of Science ®Google Scholar
• Lahl M, Fisher VL, Laschinger K. 2008. Ewing’s sarcoma family of tumors: an overview from diagnosis to survivorship. Clin J Oncol Nurs. 12:89–97.10.1188/08.CJON.89-97
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim MM. 2011. Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sci. 88:465–472.10.1016/j.lfs.2011.01.005
   PubMed Web of Science ®Google Scholar
• Li Y, Bäckesjö CM, Haldosén LA, Lindgren U. 2009. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol. 609:13–18.10.1016/j.ejphar.2009.03.004
   PubMed Web of Science ®Google Scholar
• Li YS, Deng ZH, Zeng C, Lei GH. 2015. Role of osteopontin in osteosarcoma. Med Oncol. 32:2093.10.1007/s12032-014-0449-y
   Web of Science ®Google Scholar
• Li YS, Deng ZH, Zeng C, Lei GH. 2016. JNK pathway in osteosarcoma: pathogenesis and therapeutics. J Recept Signal Transduct Res. 36:465–470.10.3109/10799893.2015.1122045
   PubMed Web of Science ®Google Scholar
• Liu Z, Li Y, Yang R. 2012. Effects of resveratrol on vascular endothelial growth factor expression in osteosarcoma cells and cell proliferation. Oncol Lett. 4:837–839.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang L, Wu Y, Lv C, Li X, Cao X, Yang M, Feng D, Luo Z. 2013. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway. Toxicology. 304:120–131.10.1016/j.tox.2012.12.018
   PubMed Web of Science ®Google Scholar
• Marques C, Ferreira JM, Andronescu E, Ficai D, Sonmez M, Ficai A. 2014. Multifunctional materials for bone cancer treatment. Int J Nanomedicine. 9:2713–2725.
   PubMed Web of Science ®Google Scholar
• Masuelli L, Marzocchella L, Focaccetti C, Tresoldi I, Palumbo C, Izzi V, Benvenuto M, Fantini M, Lista F, Tarantino U, et al. 2012. Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci (Landmark Ed). 17:498–508.10.2741/3940
   PubMed Web of Science ®Google Scholar
• Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli M. 2006. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem. 281:2911–2922.10.1074/jbc.M508683200
   PubMed Web of Science ®Google Scholar
• Miao J, Wu S, Peng Z, Tania M, Zhang C. 2013. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 34:2093–2098.10.1007/s13277-013-0940-7
   PubMed Web of Science ®Google Scholar
• Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. 2016. Anticancer efficacy of polyphenols and their combinations. Nutrients. 8:552.10.3390/nu8090552
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. 2009. The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13.10.1007/978-1-4419-0284-9
   PubMedGoogle Scholar
• Owen LA, Kowalewski AA, Lessnick SL. 2008. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS ONE. 3:e1965.10.1371/journal.pone.0001965
   PubMed Web of Science ®Google Scholar
• Park JS, Kim KM, Kim MH, Chang HJ, Baek MK, Kim SM, Jung YD. 2009. Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 expression. Anticancer Res. 29:355–362.
   PubMed Web of Science ®Google Scholar
• Pham-Marcou TA, Beloeil H, Sun X, Gentili M, Yaici D, Benoit G, Benhamou D, Mazoit JX. 2008. Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: Prolonged effect related to COX-2 expression impairment. Pain. 140:274–283.10.1016/j.pain.2008.08.010
   PubMed Web of Science ®Google Scholar
• Pirola L, Fröjdö S. 2008. Resveratrol: One molecule, many targets. IUBMB Life. 60:323–332.10.1002/(ISSN)1521-6551
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, et al. 2008. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström’s macroglobulinemia. Clin Cancer Res. 14:1849–1858.10.1158/1078-0432.CCR-07-1750
   PubMed Web of Science ®Google Scholar
• Rusin M, Zajkowicz A, Butkiewicz D. 2009. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev. 130:528–537.10.1016/j.mad.2009.06.005
   PubMed Web of Science ®Google Scholar
• Song H, Han Y, Pan C, Deng X, Dai W, Hu L, Jiang C, Yang Y, Cheng Z, Li F, et al. 2015. Activation of adenosine monophosphate-activated protein kinase suppresses neuroinflammation and ameliorates bone cancer pain: involvement of inhibition on mitogen-activated protein kinase. Anesthesiology. 123:1170–1185.10.1097/ALN.0000000000000856
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Kahl M, Siranjeevi PM, Blumrich A, Blümel L, Becker S, Wittig S, Winkler R, Krämer OH, Beck JF. 2016. Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing’s sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity. J Cancer Res Clin Oncol. 142:17–26.10.1007/s00432-015-1994-2
   PubMed Web of Science ®Google Scholar
• Sridhar H, Vijaya M, Clement W, Srinivas C. 2014. Chondrosarcoma arising in an enchondroma of the metacarpal bone–a case report. J Clin Diagn Res. 8:142–143.
   PubMedGoogle Scholar
• Su JL, Yang CY, Zhao M, Kuo ML, Yen ML. 2007. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem. 282:19385–19398.10.1074/jbc.M702452200
   PubMed Web of Science ®Google Scholar
• Sulkowski JP, Raval MV, Browne M. 2013. Margin status and multimodal therapy in infantile fibrosarcoma. Pediatr Surg Int. 29:771–776.10.1007/s00383-013-3318-4
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang H, Liu M, Lin F, Hua J. 2015. Resveratrol abrogates the effects of hypoxia on cell proliferation, invasion and EMT in osteosarcoma cells through downregulation of the HIF-1α protein. Mol Med Rep. 11:1975–1981.10.3892/mmr.2014.2913
   PubMed Web of Science ®Google Scholar
• Thacker MM, Temple HT, Scully SP. 2005. Current treatment for Ewing’s sarcoma. Expert Rev Anticancer Ther. 5:319–331.10.1586/14737140.5.2.319
   PubMed Web of Science ®Google Scholar
• Tian J, He H, Lei G. 2014. Wnt/β-catenin pathway in bone cancers. Tumour Biol. 35:9439–9445.10.1007/s13277-014-2433-8
   PubMed Web of Science ®Google Scholar
• Venturelli S, Berger A, Böcker A, Busch C, Weiland T, Noor S, Leischner C, Schleicher S, Mayer M, Weiss TS,et al. 2013. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One. 8:e73097.10.1371/journal.pone.0073097
   PubMed Web of Science ®Google Scholar
• Wang H, Yang YL, Zhang H, Yan H, Wu XJ, Zhang CZ. 2014. Administration of the resveratrol analogues isorhapontigenin and heyneanol-A protects mice hematopoietic cells against irradiation injuries. Biomed Res Int. 2014:282657.
   PubMed Web of Science ®Google Scholar
• Willson CM, Grundmann O. 2017. In vitro assays in natural products research - a matter of concentration and relevance to in vivo administration using resveratrol, α-mangostin/γ-mangostin and xanthohumol as examples. Nat Prod Res. 31:492–506.10.1080/14786419.2016.1190721
   PubMed Web of Science ®Google Scholar
• Wojcik JB, Bellizzi AM, Dal Cin P, Bredella MA, Fletcher CD, Hornicek FJ, Deshpande V, Hornick JL, Nielsen GP. 2014. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series. Am J Surg Pathol. 38:1538–1544.10.1097/PAS.0000000000000265
   PubMed Web of Science ®Google Scholar
• Xu G, Kuang G, Jiang W, Jiang R, Jiang D. 2016. Polydatin promotes apoptosis through upregulation the ratio of Bax/Bcl-2 and inhibits proliferation by attenuating the β-catenin signaling in human osteosarcoma cells. Am J Transl Res. 8:922–931.
   PubMed Web of Science ®Google Scholar
• Yang SF, Lee WJ, Tan P, Tang CH, Hsiao M, Hsieh FK, Chien MH. 2015. Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas. Oncotarget. 6:2736–2753.10.18632/oncotarget.v6i5
   PubMed Web of Science ®Google Scholar
• Yang SD, Ma L, Yang DL, Ding WY. 2016. Combined effect of 17β-estradiol and resveratrol against apoptosis induced by interleukin-1β in rat nucleus pulposus cells via PI3 K/Akt/caspase-3 pathway. Peer J 4:e1640.10.7717/peerj.1640
   PubMed Web of Science ®Google Scholar
• Yeo SC, Ho PC, Lin HS. 2013. Pharmacokinetics of pterostilbene in Sprague-Dawley rats: The impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol Nutr Food Res. 57:1015–1025.10.1002/mnfr.v57.6
   PubMed Web of Science ®Google Scholar
• Yeo SCM, Fenwick PS, Barnes PJ, Lin HS, Donnelly LE. 2017. Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. Br J Pharmacol. 174:2043–2059.10.1111/bph.13803
   PubMed Web of Science ®Google Scholar
• Zou Y, Yang J, Jiang D. 2015. Resveratrol inhibits canonical Wnt signaling in human MG-63 osteosarcoma cells. Mol Med Rep. 12:7221–7226.10.3892/mmr.2015.4338
   PubMed Web of Science ®Google Scholar